Neuroinflammation is a complex integration of the responses of all cells present within the CNS, including the neurons, macroglia, microglia and the infiltrating leukocytes. The initiating insult, environmental factors, genetic background and age/past experiences all combine to modulate the integrated response of this complex neuroinflammatory circuit. Here, we explore how these factors interact to lead to either neuroprotective versus neurotoxic inflammatory responses. We specifically focus on microglia and astrocytic regulation of autoreactive T cell responses.
Introduction: what is inflammation?
Throughout the body, direct injury to a tissue induces immediate local inflammatory responses followed by systemic recruitment of immune cells [1, 2] . The degree and extent of inflammation is a function of the interplay between (a) the initiating insult (pathogen and/or tissue trauma), (b) the local stromal cells and (c) the peripheral immune system [1, 2] . A successful inflammatory response not only eliminates any invading pathogens, but it actively promotes wound healing and angiogenesis [1] . By contrast, chronic and/or progressive inflammatory disease can result from a failure to remove or resolve the initiating insult or from the dysregulated injury response of either the affected tissue or the recruited immune system [1] .
Although the CNS is an immune privileged site, (reviewed in [3]), inflammatory reactions can and do occur within the CNS [4] . Indeed, neuroinflammation is now recognized to be a prominent feature of many classic neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, Parkinson's disease, narcolepsy and even autism [5, 6] ! However, in all of these disorders, the role that neuroinflammation may be playing in wound healing (i.e., in neurorepair/neuroprotection) has received less attention than the role it likely plays in cytodestruction (i.e., neurodegeneration) [4, 7] . Furthermore, in chronic or remitting/relapsing neurodegenerative disorders, inflammation is unlikely to be playing a purely beneficial versus detrimental function [3] . These distinctions are not of merely academic importance. Several recent clinical trials have tested the efficacy of different types of immune therapies for treating Alzheimer's disease (AD) and multiple sclerosis (MS) [8] [9] [10] . In the AD clinical trial, the goal was to direct the immune system to targeted destruction of amyloid plaques [8] . In the multiple sclerosis trial, the goal was to prevent T cell infiltration into the CNS [11] . Surprisingly, both trials were halted for unexpected forms of CNS inflammation. In the Alzheimer's trial, approximately 6% of the patients developed encephalitis. As yet there is debate as to the efficacy of inducing an auto-amyloid responses and even whether the induction of encephalitis was in the final analysis detrimental or beneficial. In the MS trial, three patients succumbed to a usually benign viral infection (PML) in a manner previously associated with immune deficiency diseases such as AIDs.
In this review, we will discuss the consequences (neuroprotection versus neurodestruction) of the very different
